Nutritional supplements that contain curcumin -- a natural anti-inflammatory compound -- may protect the eyes from the ...

The therapy, called photobiomodulation or “red light” therapy, can reduce the risk of vision loss and slow progression of the ...

A new statistical models shed light on why some patients can extend the dosing interval with Eylea (aflibercept) from 8 weeks ...

CHICAGO -- Availability of a bevacizumab biosimilar for ophthalmic use could eliminate a lower-cost treatment option for a ...

Alkeus Pharmaceuticals’ study results from Gildeuretinol shows significant trend in slowing geographic atrophy: Cambridge, Massachusetts Friday, October 25, 2024, 10:00 Hrs [IST ...

CHICAGO -- An artificial intelligence (AI)-based study of home monitoring for neovascular age-related macular degeneration ...

In the last 20 years, there have been rapid advances in the treatment options ... patients with myopic macular degeneration complicated by CNV may benefit from a new ophthalmic frontier of ...

Data about higher doses that are injected less often come as the original 2-milligram dose of Eylea is facing an increasing ...

Regenxbio and AbbVie announced positive Phase II results for gene therapy ABBV-RGX-314 in wet AMD, showing a 97% reduction in ...

Age-related macular degeneration (AMD) is one of the leading causes of vision ... researchers are still looking for more accessible and affordable treatments for all forms of AMD. Since AMD is closely ...

According to a study presented at the American Academy of Ophthalmology’s annual meeting in Chicago, investigational ...

By squeezing Regeneron’s Eylea, eye disease drug Vabysmo has become one of the biggest growth drivers for Roche. | Despite ...